Roche Diabetes Care to Highlight Leading Patient Health and Safety Initiatives at the American Diabetes Association Annual Conference
Roche Diabetes Care, makers of the ACCU-CHEK® portfolio of diabetes management products and services, will highlight leading patient health and safety initiatives during the 70th annual American Diabetes Association Annual Conference June 26-28 in Orlando, FL.
“During the past year, Roche Diabetes Care has made significant advancements in health and safety initiatives to assist health care professionals and patients make personal discoveries in managing their diabetes,” said Luc Vierstraete, senior vice president and general manager, Roche Diabetes Care North America. “We will be sharing these advances with our clinical partners and other leaders in diabetes care during the ADA annual conference.”
Highlights from Roche Diabetes Care at ADA will include:
- An interactive, hands-on demonstration of the company’s industry recommendations for the production and performance of blood glucose systems. These recommendations, called “Total System Performance,” were unveiled during a March 2010 Food and Drug Administration public meeting and continue to be the most comprehensive set of guidelines to help ensure patient safety for those living with diabetes in the United States. This display will be housed in the ACCU-CHEK booth (#1401) in the Orange County Convention Center, West Building, Exhibit Halls B-D and will be available for demonstration Saturday, June 26 from 10:00 a.m.-4:00 p.m., Sunday, June 27 from 10:00 a.m.-4:00 p.m. and Monday, June 28 from 10:00 a.m.-2:00 p.m.
- One-on-one tutorials of the company’s Patient Engagement Toolkits. These toolkits, unique industry firsts included in every ACCU-CHEK meter, help people living with diabetes to better manage the disease by helping individuals to make personal discoveries about their blood sugar numbers and what they mean to their daily lives. The toolkits include an educational DVD, a prescription discount card and interactive information about structured blood glucose testing. Pediatric and Spanish-language versions of the toolkits are also available. Prior to ADA, more information can be found at www.accu-chekconnect.com.
- Results of a new study regarding the positive impacts of structured blood glucose testing in non-insulin treated people with Type 2 diabetes. William Polonsky, PhD, CDE, will present the poster, “Structured SMBG Significantly Reduces A1c Levels in Poorly Controlled, Non−insulin Treated Type 2 Diabetes: Results from the STeP Study,” from noon-2 p.m. on Sunday, June 27, in the Orange County Convention Center, West Building, Exhibit Hall C.
Representatives from Roche Diabetes Care will be available to answer questions about these and other initiatives at the ACCU-CHEK booth (#1401) in the Orange County Convention Center, West Building, Exhibit Halls B-D, Saturday, June 26 from 10:00 a.m.-4:00 p.m., Sunday, June 27 from 10:00 a.m.-4:00 p.m. and Monday, June 28 from 10:00 a.m.-2:00 p.m.
For information prior to ADA or to set up interviews with Roche executives during ADA please contact Todd Siesky, public relations manager for Roche Diabetes Care, at (317) 521-3966 or email@example.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients’ condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care